Sign in
Not yet recruitingNo phase

Lab maturation of eggs for women with infertility

Tests maturing eggs in the lab, called CAPA-IVM, in women with infertility.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
CAPA In-vitro Oocyte Maturation (CUHK Medical Centre Limited)
Status
Not yet recruiting
People taking part
50 people, planned
Started
1 Aug 2025
Expected to end
1 Jul 2036
Type of study
Interventional
Treatments tested
  • CAPA-IVM
Record updated
24 July 2025

Who can take part

The trial is looking for women aged 18 to 50 who want to preserve their fertility or have eggs collected. The eggs are matured in the lab (CAPA-IVM).

Age
18 to 50 years
Sex
Women only
Main reasons for not taking part
  • People who cannot give consent, for example because of serious mental health problems or cognitive delay
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Patients aged from 18-50 years old
  • Patients seek fertility preservation services
  • Patients seek oocyte retrieval services

Who cannot take part

  • Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sex
  • Female infertility

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

The group in the trial

  • CAPA-IVMTreatment being tested

    In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CAPA In-vitro Oocyte Maturation
Plain-language title
Lab maturation of eggs for women with infertilityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07083427, who can take part
Record updated
24 July 2025